These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31693563)

  • 1. A Study of Tolerability, Satisfaction, and Cost Reduction Using a 10% Immunoglobulin Product at Higher Administration Rates.
    Bauer S; Fadeyi M; Chan S
    J Infus Nurs; 2019; 42(6):297-302. PubMed ID: 31693563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex
    Wasserman RL; Melamed IR; Stein MR; Jolles S; Norton M; Moy JN;
    J Clin Immunol; 2017 Apr; 37(3):301-310. PubMed ID: 28316003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gammaplex
    Wasserman RL
    Immunotherapy; 2017 Oct; 9(13):1071-1088. PubMed ID: 29032734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease.
    Kriván G; Königs Ch; Bernatowska E; Salama A; Wartenberg-Demand A; Sonnenburg C; Linde R
    Vox Sang; 2015 Oct; 109(3):248-56. PubMed ID: 25953213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of Infusion Time Using a 10% Intravenous Immunoglobulin Formulation With a 15-Minute Rate Escalation Protocol During Staffing Shortages Due to COVID-19.
    Prosser B; Walton TP; Miller C
    J Infus Nurs; 2022 Nov-Dec 01; 45(6):299-305. PubMed ID: 36322947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
    Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
    Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
    Borte M; Kriván G; Derfalvi B; Maródi L; Harrer T; Jolles S; Bourgeois C; Engl W; Leibl H; McCoy B; Gelmont D; Yel L
    Clin Exp Immunol; 2017 Jan; 187(1):146-159. PubMed ID: 27613250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.
    Shapiro RS
    Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with Subgam, a Subcutaneously Administered Human Normal Immunoglobulin (ClinicalTrials.gov--NCT02247141).
    Dash C; Gascoigne E; Gillanders K; Gooi H
    PLoS One; 2015; 10(7):e0131565. PubMed ID: 26222441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of increased rate of infusion of intravenous immunoglobulin G, 10% in antibody-deficient patients.
    Gelfand EW; Hanna K;
    J Clin Immunol; 2006 May; 26(3):284-90. PubMed ID: 16783467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kiovig for primary immunodeficiency: reduced infusion and decreased costs per infusion.
    Connolly M; Simoens S
    Int Immunopharmacol; 2011 Sep; 11(9):1358-61. PubMed ID: 21570491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency.
    Geng B; Clark K; Evangelista M; Wolford E
    Front Immunol; 2022; 13():1075527. PubMed ID: 36818468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nursing guidelines for administration of immunoglobulin replacement therapy.
    Younger ME; Aro L; Blouin W; Duff C; Epland KB; Murphy E; Sedlak D;
    J Infus Nurs; 2013; 36(1):58-68. PubMed ID: 23271153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases.
    Berger M; Pinciaro PJ;
    J Clin Immunol; 2004 Jul; 24(4):389-96. PubMed ID: 15163895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
    Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
    Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment.
    Rosenbach K; Park M; Sanchirico M; Nwose O; Paris K
    J Clin Immunol; 2023 Jul; 43(5):912-920. PubMed ID: 36809598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
    Shapiro RS
    Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety monitoring of the intravenous immunoglobulin preparation Intratect® in primary and secondary immunodeficiencies: a prospective non-interventional study.
    Bauhofer A; Dietrich RL; Schmeidl R
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):21-31. PubMed ID: 25345431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
    Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
    Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
    Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
    Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.